Richard Bourgon, South San Francisco, CA (US); David Fabrizio, Cambridge, MA (US); Gregg Fine, South San Francisco, CA (US); Garrett M. Frampton, Cambridge, MA (US); Priti Hegde, South San Francisco, CA (US); Sanjeev Mariathasan, South San Francisco, CA (US); Philip J. Stephens, Cambridge, MA (US); James Xin Sun, Cambridge, MA (US); and Roman Yelensky, Newton, MA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US); and Foundation Medicine, Inc., Cambridge, MA (US)
Filed by Genentech, Inc., South San Francisco, CA (US); and Foundation Medicine, Inc., Cambridge, MA (US)
Filed on Feb. 2, 2022, as Appl. No. 17/590,918.
Application 17/590,918 is a continuation of application No. 16/115,343, filed on Aug. 28, 2018, granted, now 11,279,767, issued on Mar. 22, 2022.
Application 16/115,343 is a continuation of application No. PCT/US2017/019682, filed on Feb. 27, 2017.
Claims priority of provisional application 62/405,190, filed on Oct. 6, 2016.
Claims priority of provisional application 62/301,595, filed on Feb. 29, 2016.
Prior Publication US 2022/0153861 A1, May 19, 2022
1. A method of treating a patient suffering from a urothelial bladder cancer, the method comprising administering to the patient a therapeutically effective amount of a PD-L1 binding antagonist, wherein a tumor sample obtained from the patient has been determined to have an increased level of mutation load relative to a reference level of mutation load, wherein mutation load of the tumor sample reflects the level of somatic mutations in at least one-third of the genes set forth in Table 1, and wherein the PD-L1 binding antagonist is an anti-PD-L1 antibody comprising a heavy chain comprising the hypervariable region (HVR)-H1 sequence of SEQ ID NO: 19, the HVR-H2 sequence of SEQ ID NO: 20, and the HVR-H3 sequence of SEQ ID NO: 21; and a light chain comprising the HVR-L1 sequence of SEQ ID NO: 22, the HVR-L2 sequence of SEQ ID NO: 23, and the HVR-L3 sequence of SEQ ID NO: 24.